• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      The Swedish Council on Health Technology Assessment (SBU)
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25471 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     HTA South [Camera-based autofluorescence during total thyroidectomy]
2026     National Institute for Health and Care Excellence (NICE) Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 1133
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Toripalimab (oesophageal carcinoma)]
2026     National Institute for Health and Care Excellence (NICE) Dupilumab for treating severe chronic rhinosinusitis with nasal polyps. NICE technology appraisal guidance 1134
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirvetuximab soravtansine (ovarian cancer)
2026     HTA Region Stockholm [Consequences of replacing chest x-ray with ultra-low-dose computed tomography in patients with a low suspicion of lung cancer]
2026     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal). NICE technology appraisal guidance 1132
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years)]
2026     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable. NICE technology appraisal guidance 1195
2026     National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1129
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Addendum to Project A25-128]
2026     National Institute for Health and Care Excellence (NICE) Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 1194
2026     National Institute for Health and Care Excellence (NICE) Obinutuzumab with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 1131
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teplizumab (type 1 diabetes mellitus, >= 8 years)
2026     National Institute for Health and Care Excellence (NICE) Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable. NICE technology appraisal guidance 1193
2026     National Institute for Health and Care Excellence (NICE) Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 1130
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotatercept (pulmonary arterial hypertension, WHO functional class IV)]
2026     National Institute for Health and Care Excellence (NICE) Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years. NICE technology appraisal guidance 1192
2026     National Institute for Health and Care Excellence (NICE) Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 1127
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gadopiclenol (contrast-enhanced magnetic resonance imaging, 0 to < 2 years)]
2026     National Institute for Health and Care Excellence (NICE) Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer. NICE technology appraisal guidance 1190
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2026     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 1128
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus in children and adolescents)]
2026     National Institute for Health and Care Excellence (NICE) Nemolizumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 1191
2026     National Institute for Health and Care Excellence (NICE) Leadless cardiac pacemaker implantation for bradyarrhythmias. NICE HealthTech guidance 770
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Donidalorsen (hereditary angioedema)]
2026     National Institute for Health and Care Excellence (NICE) Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment. NICE HealthTech guidance 781
2026     National Institute for Health and Care Excellence (NICE) Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation. NICE HealthTech guidance 771
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction)]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Latent infection screening before initiating immunosuppressive cancer treatment]
2026     National Institute for Health and Care Excellence (NICE) Pulmonary artery pressure technologies for remote monitoring of chronic heart failure. NICE HealthTech guidance 769
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; adjuvant treatment)]
2026     National Institute for Health and Care Excellence (NICE) Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. NICE highly specialised technologies guidance 34
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teprotumumab (thyroid eye disease)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (acute myeloid leukaemia)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (cholangiocarcinoma)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B): Review of the study protocol (Version 4.0) and the statistical analysis plan (Version 4.0) – Fourth addendum to Project A22-83 (RPDC concept)]
2026     Swiss Federal Office of Public Health (FOPH) Superficial/deep heat in physiotherapy for musculoskeletal conditions
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (COPD)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inebilizumab (immunoglobulin G4-related disease)]
2026     Swiss Federal Office of Public Health (FOPH) Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy
2026     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inebilizumab (generalized myasthenia gravis)]
2026     Swiss Federal Office of Public Health (FOPH) Thermoablation for benign thyroid nodules
2026     NIHR Health Services and Delivery Research programme Digital alerting to improve sepsis detection and patient outcomes in NHS Trusts: a multi-methods study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (indolent systemic mastocytosis) – Addendum to Project A25-136]
2026     NIHR Health Technology Assessment programme Effectiveness of polyhexanide, chlorhexidine with neomycin and mupirocin for nasal methicillin-resistant Staphylococcus aureus (MRSA) decolonisation: non-inferiority RCT (TIDE)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Donanemab (early Alzheimer’s disease) – Addendum to Project A25-134]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imlunestrant (breast cancer)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib/abiraterone acetate (prostate cancer)]
2026     NIHR Health Technology Assessment programme Views on outpatient paracentesis and GnRH antagonists for ovarian hyperstimulation syndrome: a qualitative study of patients and healthcare professionals
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezepelumab (chronic rhinosinusitis with nasal polyps) – Addendum to Project A25-145]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Addendum to Project A25-147]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Targeted lung denervation using catheter ablation in patients with moderate to severe chronic obstructive pulmonary disease that cannot be treated or cannot be adequately treated with medication]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elinzanetant (vasomotor symptoms in menopause)]
2026     NIHR Health Technology Assessment programme Removal of small fibroids and polyps in patients with infertility and recurrent miscarriage: The HELP Fertility? RCT
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elinzanetant (vasomotor symptoms associated with breast cancer treatment)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Depemokimab (asthma)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Depemokimab (chronic rhinosinusitis with nasal polyps)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone)]
2026     Health Information and Quality Authority (HIQA) Rapid health technology assessment on the use of vesicostomy buttons in children
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma; combination with pomalidomide and dexamethasone)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (CML, first- and second-line treatment) – Addendum to Project A25-150]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma, neoadjuvant and adjuvant) – Addendum to Project A25-148]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmale nächtliche Hämoglobinurie) - Addendum zum Projekt A25-156]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Addendum to Project A25-155]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma, adjuvant) – Addendum to Project A25-154]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nipocalimab (generalized myasthenia gravis) – Addendum to Project A25-160]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer, non-advanced) – Addendum to Project A25-96]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafasitamab (follicular lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Donanemab (early Alzheimer’s disease)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Second addendum to Project A25-128]
2026     Health Technology Wales (HTW) Capsule sponge devices to detect Barrett’s oesophagus and early-stage oesophageal cancer
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (indolent systemic mastocytosis)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegcetacoplan (complement 3 glomerulopathy]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (advanced systemic mastocytosis)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegcetacoplan (primary immune-complex membranoproliferative glomerulonephritis, >= 12 years) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vimseltinib (symptomatic tenosynovial giant cell tumours) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanidatamab (biliary tract cancer, HER2-positive [IHC3-positive], previously treated)]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure with reduced left ventricular ejection fraction (LVEF < 40 %) – Addendum to Project N24-04]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imipenem/Cilastatin/Relebactam (bacterial infections, several therapeutic indications, < 18 years)]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Barriers and facilitators when implementing guidelines in health and social care for the elderly]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vorasidenib (astrocytoma or oligodendroglioma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Retifanlimab (Merkel cell carcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Retifanlimab (squamous cell carcinoma of the anal canal)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (CML, first- and second-line treatment)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (CML, first- and second-line treatment) – Second addendum to Project A25-150]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olezarsen (chylomicronaemia syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of ‘ThemenCheck Medizin’ (Topic check medicine) with regard to the HTA domains of ethical, social, legal and organizational aspects, and health economics]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for carotid revascularization surgery for carotid stenosis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Reducing the effort required in guideline search and selection]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Important new EBM-relevant methods 2024/2025 – Medical Biometry]
2026     Agency for Care Effectiveness (ACE) Phagenyx to improve swallowing in severe post-stroke dysphagia
2026     Basque Office for Health Technology Assessment (OSTEBA) [Molecular diagnosis of drug-resistant microorganisms]
2026     NIHR Health Technology Assessment programme Surgery for early structural osteoarthritis of the hip and knee: the SCORE evidence synthesis and economic evaluation
2026     NIHR Health Services and Delivery Research programme Improving medicines use in people with polypharmacy in primary care: a synopsis from the IMPPP cluster-RCT with pilot-feasibility study